Bringing you live news and features since 2006 

Announcement

BioShares Biotechnology ETFs complete semi-annual rebalance and recomposition BBC and BBP

RELATED TOPICS​

LifeSci Index Partners has completed its semi-annual rebalancing and recomposition for its BioShares Biotechnology exchange-traded funds (ETFs), which trade under the symbols BBC and BBP on Nasdaq. 

These passively-managed funds are designed to track their respective, rules-based indexes. Both funds have increased in number of holdings, and have rebalanced to equally weight position sizes.

The BioShares Biotechnology Funds are the only ETFs to separate Clinical Trials stage companies and Products stage companies into two distinct funds. The BioShares Biotechnology Clinical Trial Fund (BBC) and BioShares Biotechnology Product Fund (BBP) offer investors exposure to these segments of the biotechnology sector while diversifying some of the risks associated with any one company.

The BBC fund has increased its number of holdings to 90 stocks (previously 67), with a weighted average capitalisation of approximately USD1.5 billion (previously USD2.1 billion). Thirty-one stocks have been added by meeting the inclusion criteria, seven stocks have moved to the BBP fund upon transitioning to the Products stage, and one stock has been removed due to signing a definitive merger agreement.

The BBP fund has increased its number of holdings to 39 stocks (previously 33), with a weighted average market cap of USD18 billion (previously USD18 billion). Seven stocks have moved from the BBC fund upon transitioning to the Products stage, and one stock has moved to the BBC fund upon transitioning back to the Clinical Trials stage.

"The high volume of changes in our rules-based BioShares portfolios reflects how quickly the biotechnology market is evolving," says LifeSci Index Partners co-founder, Paul Yook. "Of the 31 new companies added to BBC, 12 have completed IPOs since 2014, and 16 focus in the cancer and immuno-oncology fields. "Record new equity issuance volume in the biotechnology sector, as well as optimism surrounding new clinical stage treatments for various cancers utilising the human body's own immune system, have been among the key drivers of the sector's continued growth.

As companies successfully complete clinical trials and transition to the commercial stage, they can move to the BioShares Products fund (BBP), when sales ramp and establishing profitability becomes more important to investors. "Robust M&A activity in the biotech sector also continues to be a dominant theme, with Product stage companies being particularly attractive targets to larger pharmaceutical companies seeking higher growth," says Andrew McDonald, PhD, CEO of LifeSci Index Partners. In the first half of 2015, three companies in the BBP fund were acquired, including NPS Pharmaceuticals, Pharmacyclics and Hyperion.

Latest News

BlackRock s iShares an undisputed leader among European ETF issuers pushed further ahead in Q1 with EUR173 billion in trades..
European ETFs raised USD47 8 billion in Q1 a 15 per cent increase compared to the same period in 2023..
LSEG Lipper s March report finds that globally equity ETFs +EUR113 2 billion enjoyed the highest estimated net inflows for..
Morningstar has published a review of the European ETF market for the first quarter 2024 which finds that it gathered..

Related Articles

etf active trading
Latest Morningstar data shows actively managed ETFs share of the US ETF market rose to 8 5 per cent at...
Kristen Mierzwa, FTSE Russell
Index Investments Group IIG a division within index provider FTSE Russell has extended its range of indices through two new...
ETFs
US ETF issuers of active ETFs are facing an increase in fees from the big custodian firms such as Charles...
Taylor Krystkowiak, Themes ETFs
Themes ETFs opened its doors in December 2023 with an introductory suite of 11 ETFs seven thematic and four fundamental...
Subscribe to the ETF Express newsletter

Subscribe for access to our weekly newsletter, newsletter archive, updates on the site and exclusive email content.

Marketing by